Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

British journal of haematology·2026
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma.

Blood·2026
Same author

TP63-rearranged ALK-negative anaplastic large-cell lymphoma post-transplant lymphoproliferative disorder: the first report of an aggressive entity.

Internal medicine journal·2026
Same author

Comparative evaluation of free light chain assays in AL amyloidosis: Performance of Sebia versus Freelite and N-Latex.

Practical laboratory medicine·2026
Same author

An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy.

Internal medicine journal·2026

Related Experiment Video

Updated: Jun 19, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Quantitative serum free light chain assay--analytical issues.

Jill Tate1, Sheree Bazeley, Stephen Sykes

  • 1Chemical Pathology Department, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. jill_tate@health.qld.gov.au

The Clinical Biochemist. Reviews
|October 21, 2009
PubMed
Summary

Serum free light chain (FLC) assays are crucial for monitoring monoclonal light chain diseases. However, assay imprecision and dilution issues can lead to inaccurate FLC concentrations and kappa/lambda ratios, potentially misguiding clinical decisions.

More Related Videos

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

Related Experiment Videos

Last Updated: Jun 19, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

Area of Science:

  • Clinical Chemistry
  • Immunodiagnostics
  • Hematology

Background:

  • Serum free light chain (FLC) assays are vital for diagnosing and monitoring monoclonal light chain diseases.
  • These assays complement traditional methods like serum protein electrophoresis and immunofixation.
  • Current assays utilize polyclonal anti-human FLC antisera on routine chemistry analyzers, detecting FLC down to ~1 mg/L.

Purpose of the Study:

  • To evaluate the analytical limitations of serum FLC assays.
  • To highlight potential sources of error affecting FLC concentration and kappa/lambda ratio accuracy.
  • To inform laboratory staff and clinicians about assay performance variability.

Main Methods:

  • Analysis of assay imprecision between reagent lots.
  • Investigation of FLC recovery across different sample dilutions.
  • Assessment of potential interferences and multi-reactivity.

Main Results:

  • Assay imprecision between reagent lots shows significant variation (8-45% for FLC, 17-32% for kappa/lambda ratio).
  • Dilution studies reveal potential over-recovery and underestimation due to nonlinear reactions.
  • Nonlinear monoclonal FLC can yield results 2- to 6-fold higher at increased dilutions; platform variability exists.

Conclusions:

  • Assay imprecision and dilution anomalies can significantly impact FLC concentration and kappa/lambda ratio interpretation.
  • These analytical limitations may mislead clinical diagnosis and treatment response assessment in monoclonal light chain disease.
  • Awareness of these limitations is crucial for accurate patient management.